Role of Senescence in the Development of Endometrial Cancer
- Conditions
- Endometrial Hyperplasia and Endometrial Cancers
- Interventions
- Genetic: Genetic analysis
- Registration Number
- NCT03338985
- Lead Sponsor
- CHU de Reims
- Brief Summary
Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of interest have been identified (P53, PTEN, PIK3CA, ß-catenin, K-ras ...).
A study has already been carried out at the Reims University Hospital with inclusion of patients with endometrial cancer and patients with endometrial hyperplasia. It identified specific alterations of nosologic continuum of pathology and characterize areas of interest on the genome.
- Detailed Description
make a pangenomic investigation of genetic abnormalities in atypical endometrial hyperplasia and endometrial cancers.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 140
- patient with endometrial hyperplasia or endometrial cancer
- patient consenting to participate to the study
- patient enrolled in the national healthcare insurance program
- patient older than 18 years
- patient with neoadjuvant chemotherapy or radiotherapy prior to surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Group "cases patients" Genetic analysis patients with endometrial hyperplasia or endometrial cancers
- Primary Outcome Measures
Name Time Method Genetic imbalances Day 0 Genetic aberrations detected by comparative genomic hybridization (CGH arry)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Damien JOLLY
🇫🇷Reims, France